Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

t is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, The Takeda Oncology Company, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 100,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neurop
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... VALLEY COTTAGE, New York , July 30, 2015 ... the release of its latest report titled, "Continuous Glucose ... 2015 - 2020". According to the report, the global ... 402.0 Mn in 2014 and is expected to reach ... 12.1% during the forecast period, 2015 to 2020. ...
(Date:7/30/2015)... AUSTIN, Texas , July 30, 2015 ... solutions company focused on gynecologic disease, announced ... 2015 financial results after the market close ... an investor conference call and webcast at ... August 13, 2015 at 4:30pm Eastern/1:30pm Pacific  ...
(Date:7/30/2015)... July 30, 2015  NanoSmart Pharmaceuticals, Inc., a ... has received Orphan Drug Designation from the Food ... product that uses NanoSmart,s proprietary drug delivery platform. ... for the treatment of Ewing,s sarcoma, a rare ... NanoSmart,s Orphan Drug Designation on the basis of ...
Breaking Medicine Technology:Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 2Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 3Global Continuous Glucose Monitoring (CGM) Systems Market: Transmitters and Monitors Most Dominant Segment, Says Future Market Insights 4NanoSmart Receives Second FDA Orphan Drug Designation for Treatment of Pediatric Cancer 2
... the release dated August 24, 2011 with the following ... and should read: The Company will provide attendees an ... Form 8K with the SEC after the close of ...  This presentation will also be available at http://ir.questcor.com/sec.cfm ...
... DOYLESTOWN, Pa., Sept. 1, 2011 ProPhase Labs (NASDAQ: ... be donating $1,000 to a well-deserving, locally nominated and ... their "Share Your Cause, Not Your Cold" contest, hosted ... registered, qualified and valid non-for-profit organization organized under the ...
Cached Medicine Technology:UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 2UPDATING and ADDING: Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September 3Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 2Help Your Favorite Charity Win $1,000 from Cold-EEZE®! 3
(Date:7/31/2015)... ... July 31, 2015 , ... Easter Seals Southern Georgia’s Heels & Wheels Duathlon & Triathlon will ... will be 7:30 AM. The duathlon is a 2 mile run, 13 mile bike ride, ... Lake, a 13 mile bike, and a 3 mile run. Heels & Wheels is ...
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/31/2015)... TN (PRWEB) , ... July 31, 2015 , ... ... Tenn. has launched a Balloon Sinuplasty website to inform potential Nashville area ... a questionnaire that can be used to determine if someone is a good ...
(Date:7/30/2015)... ... July 31, 2015 , ... When responsible for the care ... out-of-reach. The questions race through your mind: What happens if mom falls? Who will ... overwhelmed and cancel your plans. , But not taking time away from caregiving responsibilities ...
(Date:7/30/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Manufacturing Floor:, Reduce Errors By 50% or More, **Presented by FDAnews and Ginette ... Dr. Ginette Collazo, a 15 year veteran of helping drug, biologic and device ...
Breaking Medicine News(10 mins):Health News:Heels & Wheels for Megan's House Set for Saturday August 22, 2015 in Waycross, Georgia 2Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 2Health News:Nashville Otolaryngologist Dr. David Gilpin Launches Balloon Sinuplasty Website 3Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 2Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 3Health News:FDAnews Announces — Reduce Human Error on the Drug and Device Manufacturing Floor: Reduce Errors By 50% or More Workshop, Sept. 16-17, 2015 4
... identified that a key protein called PEA-15 stops T-cell proliferation ... T-cell proliferation is essential in preventing certain blood cancers and ... response to infection. Findings of the study are reported ... , a publication of The Federation of American Societies for ...
... Boston with its famed medical institutions for a ... Combating Disease"? This historic Northeast city will, in fact, ... Chemical Society,s (ACS,) 240th National Meeting & Exposition, Aug. 22-26. ... print, broadcast, and online journalists a rich assortment of spot ...
... ... , ... May 4, 2010 -- Bold Software recently announced the second annual release of a ... technology. That study, combined with the company’s recent benchmarking analysis, shows that not ...
... the more cigarettes a woman smoked, the greater the ... woman who smokes while pregnant increases her baby,s risk ... a new Finnish study suggests. , While there,s plenty ... at risk for long-term health problems such as asthma, ...
... ... offers a potential boon to the diagnostic lab industry in the form of new business, ... lab industry expert Dennis Weissman at a Slone Partners teleconference on the new law April ... Miami, FL (PRWEB) ...
... ... partnership with Strategic Insight Publishing, took a step further with the release of ... Relationships. , ... 2010 -- Quoting verses from the book, the Founder and CEO of Myeexpert, Dr. Joel ...
Cached Medicine News:Health News:Study finds key protein controls T-cell proliferation 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 2Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 3Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 4Health News:Fear of Proactive Chat Unfounded According to Research by Bold Software 5Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 2Health News:Smoking While Pregnant May Raise Psychiatric Risks in Kids 3Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 2Health News:Lab Industry Likely to Benefit from Expanded Preventive Testing Under New Health Care Law 3Health News:“You Are Very Pretty”, Says Myeexpert As It Releases A Book, Poetic Expressions, Dedicated To The Beauty of Women. 2
... The Sysmex pocH-100i is the first ... with low daily testing requirements. With its ... 3-part differential from just 15 L of ... for any small healthcare site including the ...
... The Ichor hematology instrument is a ... When used with Plateletworks reagents, the Ichor ... standard CBC with platelet count plus platelet ... simple. A fresh whole blood sample is ...
... family, which includes the world's smallest ... most advanced pacemaker technology available, including ... first and only U.S. commercially approved ... (AF). The AF Suppression algorithm in ...
... CryoTherapy system uses catheters that are ... refrigeration console. The console processes the ... distal tip of the catheter, creates ... through an easy-to-use touch-screen interface. From ...
Medicine Products: